Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/14/2025 | $62.00 | Outperform | Raymond James |
| 7/11/2025 | $52.00 | Overweight | Cantor Fitzgerald |
| 6/12/2025 | $78.00 | Overweight | Piper Sandler |
| 5/21/2025 | $65.00 | Outperform | Oppenheimer |
| 5/15/2025 | $55.00 | Buy | BTIG Research |
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
10-Q - Tvardi Therapeutics, Inc. (0001346830) (Filer)
SCHEDULE 13G - Tvardi Therapeutics, Inc. (0001346830) (Subject)
Raymond James initiated coverage of Tvardi Therapeutics with a rating of Outperform and set a new price target of $62.00
Cantor Fitzgerald initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $52.00
Piper Sandler initiated coverage of Tvardi Therapeutics with a rating of Overweight and set a new price target of $78.00
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4/A - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 4, 2025 at 2:10 PM EDT and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the webcast will be available for approximately 90 days following the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company
On track for multiple Phase 2 data readouts with STAT3 inhibitor, TTI-101, with lead program in IPF expected in Q4 2025 Cash runway anticipated to be sufficient to fund operations into Q4 2026 Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the second quarter ended June 30, 2025, and provided a business update. Second Quarter 2025 Highlights: Announced completion of enrollment in its REVERT IPF clinical trial, a Phase 2 trial of TTI-101, for patients with idiopathic
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company's Management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30, 2025 at 4:40 PM ET and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the webcast will be available for approximately 60 days following the conference. About Tvardi Therapeutics Tvardi is a clinical-stage biopharmaceutical company fo